Molecular profiling and risk stratification of adenocarcinoma of the colon.
Staging systems are used to predict the clinical and biologic behavior of tumors. This manuscript examines several molecular markers that hope to improve staging for colon cancer. It is unclear if a molecular marker, genetic signature, or a combination of histologic, genetic, and molecular parameters will provide the best prognostic information. What is clear is that more accurate staging tools are needed so patients receive the best therapy.
Mutch
Matthew G
MG
Department of Surgery, Washington University School of Medicine, St. Louis, Missouri 63110, USA. mutchm@wudosis.wustl.edu
D000230:Adenocarcinoma / Q000235:genetics* / Q000473:pathology; D014408:Biomarkers, Tumor / Q000235:genetics; D003110:Colonic Neoplasms / Q000235:genetics* / Q000473:pathology; D020869:Gene Expression Profiling / Q000379:methods*; D016147:Genes, Tumor Suppressor; D005819:Genetic Markers / Q000235:genetics; D006801:Humans; D053842:Microsatellite Instability; D009367:Neoplasm Staging; D009857:Oncogenes / Q000235:genetics; D011379:Prognosis; D018570:Risk Assessment
D014408:Biomarkers, Tumor; D005819:Genetic Markers